Panthera Biopartners has secured private equity investment from Lloyds Development Capital

Panthera Biopartners had secured growth capital from Lloyds Development Capital Limited (LDC) to advance its geographic presence and enhance its clinical offering.

Panthera is one of the UK’s largest site management organizations (SMOs) for commercial clinical trials. Based in Preston, Lancashire, Panthera specializes in patient recruitment and the management of Phase II and Phase III clinical trials across a broad spectrum of therapeutic areas, including vaccines, cardiovascular medicine, diabetes, neurology, respiratory medicine, dermatology, rheumatology and early dementia. Its services span trial planning, data collection and patient retention. Operating six UK sites, Panthera conducts clinical trials for many of the world’s largest pharmaceutical companies and clinical research organizations (CROs).

LDC is a mid-market UK private equity firm. With LDC’s support, Panthera will seek to further expand its operations across the UK and Europe, increase the number of clinical sites, invest in technology and scale its trial delivery capabilities. As SMOs play an increasingly pivotal role in the drug development value chain, the business is well-positioned to capitalize on significant growth opportunities.

“We’re incredibly proud of what the team at Panthera has achieved and are excited to partner with LDC for this next phase of growth. Their investment will help us accelerate expansion, enhance our capabilities and continue delivering for our clients and patients. With LDC’s support and experience, we look forward to broadening our reach into Europe and expanding access to clinical trials across new regions,” said Stuart Young, CEO of Panthera.

Oaklins S&W, based in the UK, acted as the management advisor to Panthera in securing private equity investment from LDC to support its ambitious growth strategy.